effects of allopurinol in the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention: a randomized clinical trial

Background: periprocedural myocardial injury (pmi) after percutaneous coronary intervention (pci) is a substantial health issue with a high mortality rate. inflammation and oxidative stress are major contributing factors to pmi. allopurinol inhibits xanthine oxidase (xo)-induced oxidative stress and has potential cardiovascular benefits. methods: this randomized clinical trial evaluated 110 patients admitted to elective pci. patients were assigned to receive either a 1200 mg loading dose of allopurinol 2 hours before the procedure (n = 55) or the standard pretreatment (n = 55). the creatine kinase-mb (ck-mb) and cardiac troponin i (ctni) levels were measured in both groups at the baseline, 8, and 24 hours after pci. results: there were no significant differences in the ck-mb levels at baseline (p = 0.71), 8 (p = 0.26), and 24 hours (p = 0.88) after pci between the two groups. no significant changes in the ctni levels at baseline (p = 0.26), 8 (p = 0.80), and 24 hours (p = 0.89) after the pci were also noted. the mean difference for ck-mb and ctni changes was not different between the two groups. conclusion: our study revealed that allopurinol did not reduce cardiac-specific enzymes. further studies are required to evaluate the impact of allopurinol on preventing pci-related myocardial injury.